Evidence map›Paper›PMID 36967338›Full record

ArticleTransplantation proceedings2023

Successful Autologous Bone Marrow Transplantation in Active COVID-19 Patients: Case Report.

Riad Amer, Ali Sabateen, Yousef El-Hamshary, Husam Salameh, Basel Hroub, Hazem Sawalhi, Osama Sawalmeh

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation proceedings, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Riad AmerHemato-oncology unit, Internal Medicine Department, An-Najah National University Hospital, An-Najah National University, Nablus, Palestine. Electronic address: Riadamer@najah.edu.
Ali SabateenInternal Medicine Department, An-Najah National University Hospital, Nablus, Palestine.
Yousef El-HamsharyInternal Medicine Department, An-Najah National University Hospital, An-Najah National University, Nablus, Palestine.
Husam SalamehHemato-oncology unit, Internal Medicine Department, An-Najah National University Hospital, An-Najah National University, Nablus, Palestine.
Basel HroubInternal Medicine Department, An-Najah National University Hospital, Nablus, Palestine.
Hazem Sawalhiand Laboratory Department, An-Najah National University Hospital, Nablus, Palestine.
Osama SawalmehInternal Medicine Department, An-Najah National University Hospital, Nablus, Palestine.
An-Najah National University · PS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with hematologic malignancies are considered at high risk for COVID-19 infection either from the disease or the treatment. Hematopoietic stem cell transplantation, one of the approved therapies for hematologic malignancies, was performed worldwide during the COVID-19 era with some regulations, such as COVID-19 testing, before proceeding with transplantation or cellular therapy. To the authors' knowledge, none have reported the result of autologous hematopoietic stem cell transplantation in an active COVID-19 patient. CASE PRESENTATION: We describe a successful clinical course of autologous bone marrow transplantation for 2 lymphoma patients who tested positive for COVID-19. A thorough discussion was conducted between multidisciplinary hemato-oncology, intensive care, and infectious diseases teams. The decision was to proceed toward bone marrow transplantation with some modifications in the transplantation protocol and close patient monitoring.

conclusionOur cases lend credence that successful autologous bone marrow transplantation is possible among active COVID-19 patients. The obstacles we faced could be overcome with collaboration between a highly qualified multidisciplinary team. Despite the potential complications, the benefits of bone marrow transplantation among patients with a high risk of relapse and who are still COVID-19-positive outweigh the risks. However, further studies are still recommended to support our inference.

Indexed as

COVID-19Hematologic NeoplasmsHematopoietic Stem Cell TransplantationBone Marrow TransplantationCOVID-19 TestingHumansNeoplasm Recurrence, LocalTransplantation, Autologous

Identifiers

PMID36967338
PMCPMC9968609
OpenAlexW4322217298

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.